Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1922 - Clinical utility of 18F-FDG PET for chemotherapy response evaluation in patients with malignant pleural mesothelioma (537P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Shingo Kanemura

Citation

Annals of Oncology (2017) 28 (suppl_10): x166-x168. 10.1093/annonc/mdx677

Authors

S. Kanemura1, K. Kuribayashi1, E. Fujimoto1, Y. Negi1, Y. Koda1, K. Mikami1, T. Minami1, T. Yokoi2, T. Kijima1

Author affiliations

  • 1 Division Of Respiratory Medicine, Department Of Internal Medicine, Hyogo College of Medicine, 663-8501 - Nishinomiya, Hyogo/JP
  • 2 Thoracic Oncology, Hyogo College of Medicine, 663-8501 - Nishinomiya, Hyogo/JP
More

Resources

Abstract 1922

Background

Efficient monitoring of tumor responsiveness to chemotherapy is essential to mitigate high mortality risks and cytotoxic effects of chemotherapeutics. However, there is no consensus on the most suitable diagnostic technique/parameters for assessing response to chemotherapy in malignant pleu- ral mesothelioma (MPM). We compared the tumor responsiveness of MPM patients as assessed using modified RECIST (mRECIST) criteria and integrated 18F-FDG-PET/CT.

Methods

Histologically confirmed MPM patients (N = 82) who were treated with three cycles of cisplatin and pemetrexed, or carboplatin and pemetrexed, were included. mRECIST and integrated 18F-FDG- PET/CT were used to evaluate MPM tumor response to chemotherapy. Metabolic non-responders were defined as those with a 25% or greater increase in SUVmax compared with the previous value. Time to progression (TTP) and overall survival (OS) were compared between metabolic-responders and non- responders.

Results

After three cycles of chemotherapy, 62 (75.6%) of the patients were classified as having SD, 15 (18%) with partial remission (PR), and 5 (6%) with progressive disease (PD), based on mRECIST criteria. The cumulative median OS was 728.0 days (95% confidence interval [CI]: 545.9–910.1) and cumulative median TTP was 365.0 days (95% CI: 296.9–433.1). For the 82 patients, the disease control rate was 93.9%, whereas the metabolic response rate was only 71.9% (p 

Conclusions

Several mRECIST confirmed SD MPM patients may be classified as metabolic non-responders on18F-FDGPET/CT. Metabolic response is significantly correlated with the median TTP, suggesting it should be included in the evaluation of the response to chemotherapy in MPM patients classified as mRECIST SD, to identify non-responders.

Clinical trial identification

Legal entity responsible for the study

Shingo Kanemura

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.